Literature DB >> 20447115

Resistant herpes simplex keratitis.

Peter R Laibson.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20447115     DOI: 10.1111/j.1442-9071.2010.02250.x

Source DB:  PubMed          Journal:  Clin Exp Ophthalmol        ISSN: 1442-6404            Impact factor:   4.207


× No keyword cloud information.
  6 in total

1.  Activation of checkpoint kinase 2 is critical for herpes simplex virus type 1 replication in corneal epithelium.

Authors:  Oleg Alekseev; Vladimir Limonnik; Kelly Donovan; Jane Azizkhan-Clifford
Journal:  Ophthalmic Res       Date:  2014-12-19       Impact factor: 2.892

2.  Nonthermal Dielectric Barrier Discharge (DBD) Plasma Suppresses Herpes Simplex Virus Type 1 (HSV-1) Replication in Corneal Epithelium.

Authors:  Oleg Alekseev; Kelly Donovan; Vladimir Limonnik; Jane Azizkhan-Clifford
Journal:  Transl Vis Sci Technol       Date:  2014-03-27       Impact factor: 3.283

3.  Inhibition of ataxia telangiectasia mutated (ATM) kinase suppresses herpes simplex virus type 1 (HSV-1) keratitis.

Authors:  Oleg Alekseev; Kelly Donovan; Jane Azizkhan-Clifford
Journal:  Invest Ophthalmol Vis Sci       Date:  2014-02-03       Impact factor: 4.799

Review 4.  Ganciclovir ophthalmic gel 0.15% for the treatment of acute herpetic keratitis: background, effectiveness, tolerability, safety, and future applications.

Authors:  Timothy Y Chou; Bennett Y Hong
Journal:  Ther Clin Risk Manag       Date:  2014-08-20       Impact factor: 2.423

5.  Partial denervation of sub-basal axons persists following debridement wounds to the mouse cornea.

Authors:  Ahdeah Pajoohesh-Ganji; Sonali Pal-Ghosh; Gauri Tadvalkar; Briana M Kyne; Daniel R Saban; Mary Ann Stepp
Journal:  Lab Invest       Date:  2015-08-17       Impact factor: 5.662

6.  HSV-1 Hijacks the Host DNA Damage Response in Corneal Epithelial Cells through ICP4-Mediated Activation of ATM.

Authors:  Oleg Alekseev; William E Donegan; Kelly R Donovan; Vladimir Limonnik; Jane Azizkhan-Clifford
Journal:  Invest Ophthalmol Vis Sci       Date:  2020-06-03       Impact factor: 4.799

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.